Portland, OR -- (SBWIRE) -- 01/11/2018 -- Hospital-acquired Infection Diagnostics Market Overview:

The Hospital-acquired Infection Diagnostics Market was valued at $2,571 million in 2016, and is expected to reach at $4,311 million by 2023. It is anticipated to register a CAGR of 7.5% during the period, 2017-2023. Hospital-acquired infections are the infections caused by bacterial, viral, and fungal pathogens. These infections can be acquired in clinical settings, such as nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can either be acquired from an infected patient, outside environment, or from the staff of that facility. The market is primarily driven by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities. However, the decline in hospital-acquired infections in the developed countries, such as U.S., Germany, and UK impedes the market growth.

The hospital-acquired infection diagnostics market is segmented based on product, test type, application, infection type, end user, and region. Based on product, the industry is split into instrument &reagents and consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. The industry finds its applications in disease testing and drug resistance testing. Furthermore, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Its end users include hospitals, clinics, ambulatory surgery centers (ASC), and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Save Upto 15% on this Report @ https://www.researchbeam.com/hospital-acquired-infection-diagnostics-market/purchase-enquiry

Drivers, Restraints, and Opportunities

Factors that accelerate growth of the hospital-acquired infection diagnostics market include rise in geriatric population base coupled with demand for hospital-acquired infection diagnostics from middle and low-income economies.

However, lack of awareness regarding hospital-acquired infection and decrease in prevalence of HAI in the developed countries act as a restraint for the market growth.

India Hospital Acquired Infection Diagnostics Market

India is expected to grow rapidly in the hospital acquired infection diagnostics market owing to increase in prevalence of nosocomial infections, such as surgical site infections and blood stream infections. According to Indian Journal of Basic and Applied Medical Research, India reported an overall growth rate for hospital acquired infections of 4.4% after conducting a research on 10,835 patients in various clinical settings.

Global Hospital Acquired Infection Diagnostics Market, by Type

Molecular diagnostics accounted for about one fourth share of the total market share in 2016and is expected to grow with a high CAGR during the forecast period. This is due to advantages of molecular diagnostics for infectious diseases, such as detection of lower amounts of infectious agents, provide an effective yet simple tool to establish efficacy of therapy, and modify treatment when appropriate.

The report provides a comprehensive analysis of the key players operating in the global hospital-acquired infection diagnostics market, such as Abbott Laboratories, AdvanDX, Alere Inc., AstraZeneca Plc, Bayer Schering Pharma LLC, Becton Dickinson and Company, Cepheid Inc., Roche AG, Daiichi Sankyo, and Hologic, Inc.

The other players of the global hospital-acquired infection diagnostics market include GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Meridien, Pfizer, and Seegene.

Get the sample PDF Brochure of market study @ https://www.researchbeam.com/hospital-acquired-infection-diagnostics-market/request-sample

Key Benefits of Hospital- Acquired Diagnostic Market Report:

It provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
It offers discussions on quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities, during the period, 2016-2023
It profiles key market players and analyzes their strategies thoroughly, which helps to understand the competitive outlook of the market
It consists of Porter's Five Forces model, which helps to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players
Hospital-acquired Infection Diagnostics Market key Segments:

By Product

Instrument & Reagents
Consumables

By Test Type

Molecular Diagnostics
Urinalysis
Immunoassay

By Application

Disease Testing
Drug-Resistance Testing

By Infection Type

Hospital Acquired Pneumonia
Bloodstream Infections
Surgical Site Infections
Gastrointestinal Infections
Urinary Tract Infections (UTI)
Others
End User

Hospital
Clinics
Ambulatory Surgery Centers (ASC)
Others
By Region

North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Turkey
South Africa
Saudi Arabia
Rest of LAMEA